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 Abstract  
Objectives: 
To develop a risk classifier using urine-derived extracellular vesicle RNA (UEV-RNA) capable of 
providing diagnostic information of disease status prior to biopsy, and prognostic information for men 
on active surveillance (AS).  
Patients and Methods: 
Post-digital rectal examination UEV-RNA expression profiles from urine (n = 535, multiple centres) 
were interrogated with a curated NanoString panel. A LASSO-based Continuation-Ratio model was 
built to generate four Prostate-Urine-Risk (PUR) signatures for predicting the probability of normal 
tissue (PUR-1), D’Amico Low-risk (PUR-2), Intermediate-risk (PUR-3), and High-risk (PUR-4) PCa. 
This model was applied to a test cohort (n = 177) for diagnostic evaluation, and to an AS sub-cohort 
(n = 87) for prognostic evaluation. 
Results: 
Each PUR signature was significantly associated with its corresponding clinical category (p<0.001). 
PUR-4 status predicted the presence of clinically significant Intermediate or High-risk disease, 
AUC = 0.77 (95% CI: 0.70–0.84). Application of PUR provided a net benefit over current clinical 
practice. In an AS sub-cohort (n=87), groups defined by PUR status and proportion of PUR-4 had a 
significant association with time to progression (p<0.001; IQR HR = 2.86, 95% CI:1.83–4.47). PUR-
4, when utilised continuously, dichotomised patient groups with differential progression rates of 10% 
and 60% five years post-urine collection (p<0.001, HR = 8.23, 95% CI:3.26–20.81).  
Conclusion: 
UEV-RNA can provide diagnostic information of aggressive PCa prior to biopsy, and prognostic 
information for men on AS. PUR represents a new & versatile biomarker that could result in 
substantial alterations to current treatment of PCa patients. 
Keywords: 
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Introduction 
The progression of prostate cancer is highly heterogeneous(1), and risk assessment at the time of 
diagnosis is a critical step in the management of the disease. Based on the information obtained prior 
to treatment, key decisions are made about the likelihood of disease progression and the best course of 
treatment for localised disease. D’Amico stratification(2), which classifies patients as Low-, 
Intermediate-, or High-risk of PSA-failure post-radical therapy, is based on Gleason score (Gs)(3), 
PSA and clinical stage, and has been used as a framework for guidelines issued in the UK, Europe and 
USA(4–6). Low-, and some favourable Intermediate-risk, patients are generally offered active 
surveillance(4,7) (AS) while unfavourable Intermediate-, and High-risk patients are considered for 
radical therapy(7). Other classification systems, such as CAPRA score(8), use additional clinical 
information, assigning simple numeric values based on age, pre-treatment PSA, Gleason score, 
percentage of biopsy cores positive for cancer and clinical stage for an overall 0-10 CAPRA score. 
The CAPRA score has shown favourable prediction of PSA-free survival, development of metastasis 
and prostate cancer-specific survival(9). 
Prostate cancer is often multifocal(10), with disease state often underestimated by TRUS biopsy 
alone(11) and overestimated by multiparametric-MRI (MP-MRI), most often in the case of Prostate 
Imaging Reporting and Data System (PI-RADS) 3 lesions(12). Sampling issues associated with 
needle biopsy of the prostate have prompted the development of non-invasive urine tests for 
aggressive disease, which examine prostate-derived material, harvested within urine(13–15). Recent 
successes in this field are illustrated by three studies carried out on whole urine for predicting the 
presence of Gs ≥ 7 on initial biopsy: Tomlins et al. (2016), and McKiernan et al. (2016) used PCA3 
and TMPRSS2-ERG transcript expression levels, whilst Van Neste et al. (2016) used HOXC6 and 
DLX1 in combination with traditional clinical markers(14,16,17). The objectives of the current study 
were to develop a urine classifier that can predict D’Amico & CAPRA risk group, and additionally 
test its utility as a predictor of disease progression, triggering the requirement for therapeutic 
intervention, within an AS cohort with five years of clinical follow-up. As a starting point we used 
167 gene probes, many previously associated with prostate cancer progression, leading to the 
development of a 36 gene classifier, deemed Prostate Urine Risk (PUR).  
Methods: 
Patient samples and clinical criteria: 
The Movember cohort comprised of first-catch post-digital rectal examination (DRE) urine samples 
collected at diagnosis between 2009 and 2015 from urology clinics at the Norfolk and Norwich 
University Hospital (NNUH, Norwich, UK), Royal Marsden Hospital (RMH, London, UK), St. 
James’s Hospital (Dublin, Republic of Ireland) and from primary care and urology clinics of Emory 
Healthcare (Atlanta, USA). Within the Movember cohort, 87 patients were enrolled on an AS 
programme at the RMH(7). AS eligibility criteria for this programme included histologically proven 
prostate cancer, age 50–80, clinical stage T1/T2, PSA < 15 ng/mL, Gs ≤ 3+3 (Gs ≤ 3+4 if age > 65), 
and < 50% percent positive biopsy cores.  Progression was defined as the detection of disease by 
clinical criteria that typically triggers the requirement for therapeutic intervention. Clinical criteria of 
progression were either: PSA velocity >1 ng/mL per year or adverse histology on repeat biopsy, 
defined as primary Gs ≥ 4 or ≥ 50% biopsy cores positive for cancer. MP-MRI criteria for progression 
were either: detection of >1 cm3 prostate tumour, an increase in volume >100% for lesions between 
0.5-1 cm
3
, or T3/4 disease(7).  
D’Amico classification used Gleason and PSA criteria as per D’Amico et al. (1998)(2). CAPRA 
classification used the criteria as described by Cooperberg et al.(2006)(8). Sample collections and 
processing were ethically approved in their country of origin: NNUH samples by the East of England 
REC, Dublin samples by St. James’s Hospital. iii) RMH by the local ethics committee, iv) Emory 
Healthcare samples by the Institutional Review board of Emory University. Trans-rectal ultrasound 
(TRUS) guided biopsy was used to provide biopsy information. Where multiple biopsies were taken 
the results from the closest biopsy to initial urine sample collection were used. Men were defined to 
have no evidence of cancer (NEC) with a PSA normal for their age or lower(18) and as such, were not 
subjected to biopsy. Metastatic disease was defined by a PSA >100 ng/mL and were excluded from 
analyses. 
Sample processing: 
For the full Movember protocol see Supplementary Methods. Briefly, urine was centrifuged (1200 g 
10 min, 6°C) within 30 min of collection to pellet cellular material. Supernatant extracellular vesicles 
(EVs) were then harvested by microfiltration as Miranda et al. (2010)(19) and RNA extracted 
(RNeasy micro kit, #74004, Qiagen). RNA was amplified as cDNA with an Ovation PicoSL WTA 
system V2 (Nugen #3312-48). 5-20 ng of total RNA was amplified where possible, down to 1 ng 
input in 10 samples. cDNA yields were mean 3.83 µg (1-6 µg). 
Expression analyses: 
NanoString expression analysis (167 probes, 164 genes, Supplementary Data) of 100 ng cDNA was 
performed at the Human Dendritic Cell Laboratory, Newcastle University, UK. 137 probes were 
selected based on previously proposed controls plus prostate cancer diagnostic and prognostic 
biomarkers within tissue and control probes (Supplementary Data). 30 additional probes were selected 
as overexpressed in prostate cancer samples when next generation sequence data generated from 20 
urine derived EV RNA (UEV-RNA) samples were analysed (unpublished). Target gene sequences 
were provided to NanoString, who designed the probes according to their protocols(20). Data were 
adjusted relative to internal positive control probes as stated in NanoString’s protocols. The ComBat 
algorithm was used to adjust for inter-batch and inter-cohort bias(21).  Data were adjusted by means 
of a correction factor (CF) for input amount by normalisation to two invariant and highly expressed 
housekeeping gene-probes, GAPDH and RPLP2. The CF for a given sample i, was calculated as the 
total mean of GAPDH and RPLP2 expression, divided by the sample-specific mean of GAPDH and 
RPLP2: 
𝐶𝐹𝑖 =  
∑ ?̅?𝐺𝐴𝑃𝐷𝐻𝑗 ,𝑅𝑃𝐿𝑃2𝑗𝑗
𝑛 × ?̅?𝐺𝐴𝑃𝐷𝐻𝑖 ,𝑅𝑃𝐿𝑃2𝑖
 
All data were expressed relative to KLK2 as follows: samples with low KLK2 (counts <100) were 
removed, and data log2 transformed. Data were further normalised by adjusting the median of each 
probe across all samples to 1, with the interquartile range adjusted to that of KLK2. More formally, for 
each sample i and gene-probe j, the KLK2 normalised value, ?̂?𝑖,𝑗was calculated as: 
?̂?𝑖,𝑗 =  
((
𝑦𝑖,𝑗  −  𝑚𝑒𝑑𝑖𝑎𝑛𝑗
𝐼𝑄𝑅𝑗
) × 𝐼𝑄𝑅𝐾𝐿𝐾2) +  𝑀𝑒𝑑𝑖𝑎𝑛𝐾𝐿𝐾2
𝑦𝑖,𝐾𝐿𝐾2
 
No correlation was seen with respect to patient’s drugs, cohort site, urine pH, colour or sample 
volume (p > 0.05; Chi-square and Spearman’s Rank tests, data not shown).  
Model production and statistical analysis: 
All statistical analyses and model construction were undertaken in R version 3.4.1(22), and unless 
otherwise stated utilised base R and default parameters.  
The Prostate Urine Risk (PUR) signatures were constructed from the training dataset as follows: for 
each probe, a univariate cumulative link model was fitted using the R package clm with risk group as 
the outcome and NanoString expression as inputs. Each probe that had a significant association with 
risk group (p < 0.05) was used as input to the final multivariate model. A constrained continuation 
ratio model with an L1 penalisation was fitted to the training dataset using the glmnetcr library(23), an 
adaption of the LASSO method(24). Default parameters were applied using the LASSO penalty and 
values from all probes selected by the univariate analysis used as input. The final multivariable model 
was selected according to the minimum Akaike information criterion and incorporated all probes not 
removed by the LASSO penalty. Ordinal logistic regression was undertaken using the ordinal 
library(25).  
Bootstrap resampling of ROC analyses used the pROC library(26) for calculation, statistical tests and 
production of figures, with 2,000 resamples used. Random predictors were generated by randomly 
sampling from a uniform distribution between 0 and 1. 
Survival analyses were undertaken where follow-up of AS patients allowed and used progression as 
an endpoint, as described above. Cox proportional hazards models utilised risk signatures as a 
continuous variable. Kaplan-Meier (KM) estimators were calculated based on the median optimal 
threshold to minimise the Log-rank test p-value from 10,000 resamples of the cohort with 
replacement to ensure robustness. The costs of missing significant cancer are far higher than an 
unnecessary biopsy or investigation. With this considered, where multiple samples were analysed 
from the same AS patient, the sample with the highest PUR-4 signature was used in survival analyses 
and KM estimators. No multiple samples from AS patients appeared simultaneously in both training 
and test datasets, minimising the potential for overfitting and bias of the model. 
Decision curve analysis (DCA)(27) examined the potential net benefit of using PUR-signatures in the 
clinic. Standardised net benefit was calculated with the rmda library(28) and presented throughout our 
decision curve analyses, as it is more interpretable when compared to net benefit(29). In order to 
ensure DCA was representative of a more general population, the prevalence of Gleason grades 
within the Movember cohort were adjusted via bootstrap resampling to match that observed in a 
population of 219,439 men that were in the control arm of the Cluster Randomised Trial of PSA 
Testing for Prostate Cancer (CAP) Trial(30). For the biopsied men within this CAP cohort, 23.6% 
were Gs 6, 8.7% Gs 7 and 7.1% Gs 8 or greater, with 60.6% of biopsies being PCa negative.  This 
was used to perform stratified random sampling with replacement of the Movember cohort to produce 
a “new” dataset of 300 samples. Standardised net benefit was calculated on the resampled dataset, and 
the process repeated for a total of 1,000 resamples. The mean standardised net benefit for PUR-4 and 
the “ treat-all” options over all iterations were used to produce the presented figures to account for 
variance in sampling.  
Results: 
The Clinical Cohort 
The Movember cohort comprised of 535 post-DRE urine samples collected from four centres 
(NNUH, n = 312; RMH, n = 87; Atlanta, n = 85; Dublin, n = 17). Multiple, longitudinal samples 
within the Movember cohort were provided by 20 of the 87 men enrolled on an AS program at the 
RMH. The median time between collection of multiple samples was 185 days (IQR: 122-252 days) 
and were treated independently from one another. Samples originated from men categorised as having 
either No Evidence of Cancer (NEC, n = 92) or localised prostate cancer at time of urine collection, 
as detected by TRUS biopsy (n = 443), that were further subdivided into three risk categories using 
D’Amico criteria: Low (L), n = 134; Intermediate (I), n = 208; and High-risk (H), n = 101. Patients 
with metastatic cancer at collection were excluded from analyses. Further characteristics of the 
Movember cohort are available in Table 1. 
Selection of EV fractions and RNA yields 
Prostate markers KLK2 and KLK3, were up to 28-fold higher in the EV fraction when compared to 
sediment (TaqMan RT-PCR, paired samples Welch t-test p < 0.001, data not shown). Based on these 
analyses and previously published results by Pellegrini et al.(31), EVs were selected for further study.  
Median UEV-RNA yields for the NNUH cohort were similar for NEC (204 ng), Low- (180 ng) and 
Intermediate-risk (221 ng) patients, and lower in High-risk (108 ng) (Supplementary Figure 1). Yields 
from three patients post-radical prostatectomy were 0.8-2 ng, suggesting that most UEV-RNA 
originates from the prostate.   
Development of the Prostate Urine Risk Signatures 
Samples in D’Amico categories Low, Intermediate and High-risk, together with NEC samples were 
divided into the Movember Training dataset (two-thirds of samples; n = 358) and the Movember Test 
dataset (one-third of samples; n = 177) by random assignment, stratified by risk category (Table 1).  
The optimal model, as defined by the LASSO criteria in a constrained continuation ratio model, (see 
methods for full details) incorporated information from 36 probes (Table 2, for model coefficients see 
Supplementary Table 1) and was applied to both training and test datasets (Figure 1A, B). For each 
sample the 4-signature PUR-model defined the probability of containing NEC (PUR-1), L (PUR-2), I 
(PUR-3) and H (PUR-4) material within samples (Figure 1A, B). The sum of all four PUR-signatures 
in any individual sample was 1 (PUR1 + PUR2 + PUR3 + PUR4 = 1). The strongest PUR-signature 
for a sample was termed the primary (1) signature while the second highest was called the secondary 
(2) signature (Figure 1C, D).  
Pre-biopsy Prediction of D’Amico risk, CAPRA score and Gleason: 
Primary PUR-signatures (PUR-1 to 4) were found to significantly associate with clinical category 
(NEC, L, I, H respectively) in both training and test sets (p < 0.001, Wald test for ordinal logistic 
regression in both Training and Test datasets, Figure 2A, B). A similar association was observed with 
CAPRA score (p < 0.001, Wald test for ordinal logistic regression in both Training and Test datasets; 
Supplementary Figure 2). 
Based on recommended guidelines(4–6), the distinction between D’Amico low and intermediate risk 
is considered critical because radical therapy is commonly recommended for patients with high and 
intermediate-risk cancer.  We therefore initially tested the ability of the PUR-model to predict the 
presence of H or I disease from L or NEC upon initial biopsy. Each of the four PUR-signatures alone 
were able to predict the presence of significant disease (Risk category ≥ Intermediate, Area Under the 
Curve (AUC) ≥ 0.68 for each PUR signature, Test dataset; Supplementary Figure 3), and were 
significantly better than a random predictor (p < 0.001, bootstrap test, 2,000 resamples). However, 
PUR-1 and PUR-4 were best at discerning significant disease and were equally effective; AUCs for 
both PUR-4 and for PUR-1 in the Training and Test cohorts were respectively 0.81 (95% CI: 0.77 - 
0.85) and 0.77 (95% CI: 0.70 - 0.84), (Figure 2C & D).   
When Gleason score alone was considered we found that PUR-4 predicted Gs ≥ 3+4 with AUCs of 
0.78 (95% CI: 0.73 - 0.82) (Training) and 0.76 (95% CI: 0.69 - 0.83) (Test) and Gs ≥ 4+3 with AUCs 
of 0.76 (95% CI: 0.70 - 0.81) (Training) and 0.72 (95% CI: 0.63 - 0.81) (Test) (Figure 3). The ability 
to predict Gs ≥ 3+4 was particularly relevant because this was previously chosen as an endpoint for 
aggressive disease in other urine biomarker studies, where  AUCs of 0.77, 0.78 and 0.74 were 
reported by McKiernan et al., 2016; Tomlins et al., 2016 and Van Neste et al., 2016, respectively. 
Decision curve analysis (DCA)(27) examined the potential net benefit of using PUR-signatures in a 
non-PSA screened population. Biopsy of men based upon their PUR-4 score provided a net benefit 
over biopsy of men based on current clinical practice across all thresholds (Figure 4). When DCA was 
also undertaken within the context of a PSA-screened population, PUR continued to provide a net 
benefit (Supplementary Figure 4). 
Active surveillance cohort: 
Within the Movember cohort were 87 men enrolled in AS at the Royal Marsden Hospital, UK. The 
median follow-up time from initial urine sample collection was 5.7 years (range 5.1 – 7.0 years) 
(Supplementary Table 2). The median time from initial urine sample collection to progression or final 
follow up was 503 days (range 0.1 – 7.4 years). The PUR profiles from these men were used to 
investigate the prognostic utility of PUR beyond categorising D’Amico Risk. The PUR profiles were 
significantly different between the 23 men who progressed within five years of urine sample 
collection, and the 49 men who did not progress (p < 0.001, Wilcoxon rank sum test; Figure 5A). 
Twenty-two men progressed by the criteria detailed above, with an additional nine men progressing 
based solely on MP-MRI criteria. Further AS cohort characteristics are available in Supplementary 
Table 2. 
Calculation of Kaplan-Meier estimators with samples divided on the basis of 1, 2 and 3°  PUR-1 
and PUR-4 signatures showed significant differences in clinical outcome (p < 0.001, log-rank test, 
Figure 5B) and was robust (log-rank test p < 0.05 in 93.6% of 100,000 cohort resamples with 
replacement, see Methods for full details). Proportion of PUR-4, a continuous variable, had a 
significant association with clinical outcome (p < 0.001; IQR HR = 5.87, 95% CI: 1.68 – 20.46); Cox 
Proportional hazards model). A robust optimal threshold of PUR-4 was determined to dichotomise AS 
patients (PUR-4 = 0.174). The two groups had a large difference in time to progression: 60% 
progression within 5 years of urine sample collection in the poor prognosis group compared to 10% in 
the good prognosis group (p < 0.001, log-rank test, Figure 5C, HR = 8.23; 95% CI: 3.26 – 20.81). 
This result is robust (p < 0.05 in 99.8% of 100,000 cohort resamples with replacement, see Methods 
for full details). 
When MP-MRI criteria for progression was also included, both primary PUR-status and dichotomised 
PUR threshold remained a significant predictor of progression (p < 0.001 log–rank test, 
Supplementary Figure 5). When the AS cohort were split by D’Amico risk category at initial urine 
collection PUR-4 remained a significant predictor of progression in men with Low-risk disease, but 
not for men with Intermediate-risk disease (p < 0.001 log–rank test, Supplementary Figure 6). 
Multiple urine specimens had been collected for 20 of the men entered into the AS trial, allowing us 
to assess the stability of urine profiles over time (Supplementary Figure 7). In patients that had not 
progressed, samples were found to be stable compared to a null model generated by randomly 
selected samples from the whole Movember Cohort (p = 0.011; bootstrap analysis with 100,000 
iterations). Samples from men deemed to have progressed failed this stability test (p = 0.059). 
Discussion: 
The variation in clinical outcome for prostate cancer, even within risk stratified groups such as 
D’Amico, is well established. Many attempts have been made to address this problem including the 
subcategorisation of intermediate risk disease into favourable and unfavourable groups(32) and the 
development of the CAPRA classification system(8). Other approaches include the development of an 
unsupervised classification framework(33) and of biomarkers of aggressive disease, as illustrated by 
Cuzick et al. (2012), Knezevic et al. (2013) and Robert et al. (2013)(34,36,37). In each of the 
examples given above, analyses are performed on cancerous tissue, usually taken at the time of 
diagnosis via needle biopsy.   
Urine biomarkers offer the prospect of a more holistic assessment of cancer status prior to invasive 
tissue biopsy and may also be used to supplement standard clinical stratification. Previous urine 
biomarker models have been designed specifically for single purposes such as the detection of 
prostate cancer on re-biopsy (PCA3 test), or to detect Gs ≥ 3+4(13,14,17,38). Here we have 
constructed the four PUR signatures to provide a non-invasive and simultaneous assessment of non-
cancerous tissue and D’Amico Low-, Intermediate- and High-risk prostate cancer in individual 
prostates. The use of individual signatures for the three D’Amico risk types is unique and could 
significantly aid the deconvolution of complex cancerous states into more readily identifiable forms 
for monitoring the development of high-risk disease in, for example AS men. 
For the detection of significant prostate cancer, PUR compares favourably to other published 
biomarkers which have used simpler transcript expression systems involving low numbers of 
probes(13,14,17,38). Here we show that the PUR classifier, based on the RNA expression levels of 36 
gene-probes, can be used as a versatile predictor of cancer aggression. Notably PCA3, TMPRSS2-
ERG and HOXC6 were all included within the optimal PUR model defined by the LASSO criteria, 
while DLX1 was not.  We first showed that the ability of PUR-4 status to predict TRUS detected 
Gs ≥ 3+4 was similar (AUC = 0.76; 95% CI = 0.69 – 0.83, Test) to these published models using 
PCA3/TMPRSS2-ERG (AUC, 0.74 - 0.78)(13,14) and HOXC6/DLX1 (AUC, 0.77)(17). 
Current clinical practice assesses patient’s disease using PSA, needle biopsy of the prostate and MP-
MRI. However, up to 75% of men with a raised PSA (≥3 ng/ml) are negative for prostate cancer on 
biopsy(6,39), whilst in absence of a raised PSA, 15% of men are found to have prostate cancer, with a 
further 15% of these cancers being high-grade(40). This illustrates the considerable need for 
additional biomarkers that can make pre-biopsy assessment of prostate cancer more accurate. In this 
respect we show that both PUR-4 and PUR-1 are each equally good at predicting the presence of 
intermediate or high-risk prostate cancer as defined by D’Amico criteria or by CAPRA status, while 
in DCA analysis we found that PUR provided a net benefit in both a PSA screened and non-PSA 
screened population of men. With the increased adoption of MP-MRI it would be useful in future 
studies to correlate PUR, and other urine-based markers, with MRI findings and radical prostatectomy 
outcomes.  
Variation in clinical outcomes are also well recognised for patients entered onto AS surveillance(41). 
We found that the PUR framework worked well when applied to men on AS monitored by PSA and 
biopsy, and also in patients monitored by MP-MRI. A potential limitation of this study is that we have 
not been able to test the PUR stratification in an independent and more conservatively managed active 
surveillance cohort. However, based on our observations approximately 13% of the RMH AS cohort 
could have been safely removed from AS monitoring for a minimum of five years. An interesting 
feature is that in some patients the PUR urine signature predicted disease progression up to five years 
before it was detected by standard clinical methods. This prognostic information could potentially 
also aid the reduction of patient-elected radical intervention in active surveillance men which in some 
cohorts can be as high as 75% within three years of enrolment(41). Indeed, we would view the use of 
PUR within the context of active surveillance as its major potential clinical application. Repeated 
longitudinal measurements of PUR status could help correctly assess and track a patient’s risk over 
time in a non-invasive manner. A future priority is to further validate the utility of PUR within active 
surveillance using other previously described longitudinal cohorts. 
In conclusion, we have shown that PUR represents a new & versatile urine biomarker system capable 
of detecting aggressive prostate cancer and predicting the need for therapeutic intervention in AS 
men. The dramatic differences in RNA expression profiles across the spectrum from high risk cancer 
to patients with no evidence of cancer, confirmed in a test cohort, can leave no doubt that the presence 
of cancer is substantially influencing the RNA transcripts found in urine EVs. We also provide 
evidence that the majority of post-DRE urine-derived EVs are derived from the prostate and that urine 
signatures are longitudinally stable.  
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Figures Legends & Tables: 
Figure 1. A) PUR profiles (PUR-1 – green, PUR-2 – blue, PUR-3 – yellow, PUR-4 – red) for the Training 
cohort, grouped by D’Amico risk group and ordered by ascending PUR-4 score. Horizontal lines indicate where 
the PUR thresholds lie for: 1° PUR-1 (Green, 0.342), 2° PUR-1 (Purple, 0.297), 1° PUR-4 (Red, 0.476), 2° 
PUR-4 (Orange, 0.219) and the crossover point between PUR-1 and PUR-4 (black, 0.123 both PUR-1 and 4). 
B) PUR profiles in the Test cohort. C) Examples of samples with primary PUR signatures, where coloured 
circles indicate the primary PUR signal for that sample; 1° PUR-1 (green), 1° PUR-2 (blue), 1° PUR-3 (yellow), 
2° PUR-4 (orange) and 1° PUR-4 (red). The sum of all four PUR-signatures in any individual sample is 1, i.e., 
PUR-1+PUR-2+PUR-3+PUR-4=1. D) The outline of the four PUR signatures for all samples ordered in 
ascending PUR-4 (red) to illustrate where 1°, 2° and the 3° crossover point of PUR-1 and PUR-4 lie. 
 
Figure 2. A & B) Boxplots of PUR signatures in samples categorised as no evidence of cancer (NEC, n = 62 
(Training), n = 30 (Test)) and D’Amico risk categories; (L – Low, n = 89 (Training), n = 45 (Test), I – 
Intermediate, n = 131 (Training), n = 69 (Test) and H – High risk, n = 61 (Training), n = 27 (Test)) in A) the 
Training and B) Test cohorts. Horizontal lines indicate where the PUR thresholds lie for: 1° PUR-1 (Green), 2° 
PUR-1 (Purple), 1° PUR-4 (Red), 2° PUR-4 (Orange). C & D) Receiver operating characteristic (ROC) curves 
of PUR-4 and PUR-1 predicting the presence of significant (D’Amico Intermediate or High risk) prostate cancer 
prior to initial biopsy in C) Training and D) Test cohorts. Coloured circles indicate the specificity and 
sensitivity, respectively, of thresholds along the ROC curve that correspond to the indicated PUR-4 thresholds, 
equivalent to: red - 1 PUR-4, orange - 2 PUR-4, purple – equivalent to 2 PUR-1, green – equivalent to 1 
PUR-1. 
 
Figure 3. AUC curves for PUR-4 predicting the presence/absence of Gleason ≥ 7 on initial biopsy in Training 
and Test cohorts (A and B, respectively) and Gleason ≥ 4+3 in Training and Test cohorts (C and D, 
respectively). Coloured circles indicate the specificity and sensitivity, respectively, of thresholds along the ROC 
curve that correspond to the indicated PUR-4 thresholds, equivalent to: red - 1 PUR-4, orange - 2 PUR-4, 
purple – equivalent to 2 PUR-1, green – equivalent to 1 PUR-1. 
Figure 4. DCA plot depicting the standardised net benefit of adopting PUR-4 as a continuous predictor for 
detecting significant cancer on initial biopsy, when significant is defined as: D’Amico risk group of 
Intermediate or greater (teal), Gs ≥ 3+4 (orange) or Gs ≥ 4+3 (red). To assess benefit in the context of cancer 
arising in a non-PSA screened population of men we used data from the control arm of the CAP study(30). 
Bootstrap analysis with 100,000 resamples was used to adjust the distribution of Gleason grades in the 
Movember cohort to match that of the CAP population.  For full details see Methods. 
 
Figure 5. A) PUR profiles of patients on active surveillance that had met the clinical criteria, not including MP-
MRI criteria, for progression (n = 23) or not (n = 49) at five years post urine sample collection. Progression 
criteria were either: PSA velocity >1 ng/ml per year or Gs ≥ 4+3 or ≥ 50% cores positive for cancer on repeat 
biopsy. PUR signatures for progressed vs non-progressed samples were significantly different for all PUR 
signature (p < 0.001, Wilcoxon rank sum test). Horizontal line colour indicates the thresholds for PUR 
categories described in: B) Kaplan-Meier plot of progression in active surveillance patients with respect to PUR 
categories described by the corresponding colours; Green - 1 and 2 PUR-1, Blue - 3 PUR-1, Yellow - 3 
PUR-4, Orange - 2 PUR-4, Red - 1 PUR-4 and the number of patients within each PUR category at the given 
time intervals in months from urine collection. C) Kaplan-Meier plot of progression with respect to the 
dichotomised PUR thresholds described by the corresponding colours Green – PUR-4 < 0.174, Red – PUR-4 ≥ 
0.174 and the number of patients within each group at the given time intervals in months from urine collection. 
  
Tables: 
Table 1. Characteristics of the Training and Test cohorts. 
Characteristic Training Test 
Total, n (%) 358 (67.0) 177 (33.0) 
Collection centre: 
  
NNUH 203 109 
RMH 83 38 
Dublin 9 8 
Atlanta 63 22 
PSA, ng/ml, mean (median; IQR) 10.6 (6.9, 6.4) 10.9 (6.9, 7) 
Age, yr, mean (median; IQR) 65.8 (67, 11) 67.2 (67, 11) 
Family history of PCa, %; no, yes, NA 3.0, 6.1, 90.8 0.6, 6.2, 93.3 
First biopsy, n (%) 298 (82.78) 145 (81.46) 
Prostate volume, ml; mean (median; IQR) 59.2 (49.8, 30.4) 61.1 (49.2, 32.8) 
PSAD, ng/ml; ml, mean (median; IQR) 0.29 (0.19, 0.16) 0.29 (0.18, 0.17) 
Suspicious DRE, n 107 52 
Diagnosis, n: 358 177 
NEC, n (%) 62 (17.3) 30 (17.0) 
D'Amico Low n (%) 89 (24.9) 45 (25.4) 
D'Amico Intermediate n (%) 139 (38.8) 69 (39.0) 
D'Amico High n (%) 61 (17.0) 27 (15.3) 
Metastatic (bone scan) n (%)* 7 (2.0) 6 (3.3) 
CAPRA, n: 288 145 
Low (0-2) n (%) 97 (33.7) 49 (33.7) 
Intermediate (3-5) n (%) 108 (37.5) 53 (36.6) 
High (≥6) n (%) 83 (28.8) 43 (29.7) 
Gleason, n: 292 144 
Gs = 6, n (%) 119 (40.8) 64 (44.4) 
Gs = 7, n (%) 131 (44.9) 56 (38.9) 
Gs ≥ 8 n (%) 42 (14.4) 24 (16.7) 
Table 2. NanoString gene probes incorporated by LASSO regularisation in the final optimal model used 
to produce the PUR signatures. 
 
 
Gene targets of nanoString probes in PUR model: 
AMACR MEX3A 
AMH MEMO1 
ANKRD34B MME 
APOC1 MMP11 
AR (exons 4-8) MMP26 
DPP4 NKAIN1 
ERG (exons 4-5) PALM3 
GABARAPL2 PCA3 
GAPDH PPFIA2 
GDF15 SIM2 (short) 
HOXC6 SMIM1 
HPN SSPO 
IGFBP3 SULT1A1 
IMPDH2 TDRD1 
ITGBL1 TMPRSS2/ERG fusion 
KLK4 TRPM4 
MARCH5 TWIST1 
MED4 UPK2 
 
 Figure 1. Cox model plots showing the difference in metastasis-free survival following SBRT and ENRT. The specific 
survival curves are for patients with median age at diagnosis (63 y), median age difference between diagnosis and 
recurrence (5y), local prostate cancer (according to EAU risk assessment), treated by radical prostatectomy at diagnosis 
and presenting with N1 disease at recurrence, no adjuvant ADT at MDT and PSA at recurrence of ≤4.  Left curve shows the 
difference between both treatment modalities for patients presenting with only one lymph node. Right curve illustrates the 
comparison between SBRT and ENRT for patients presenting with more than one lymph node at recurrence. ENRT: elective 
nodal radiotherapy; SBRT: stereotactic body radiotherapy 
 
 
 
 
 
Figure 2: General overview of the observed toxicities in both treatment groups. A: early toxicity. B: late toxicity. ENRT: elective nodal 
radiotherapy; MDT: metastasis-directed therapy; SBRT: stereotactic body radiotherapy 
 
 
 
 
  
Supplementary material 
 
Supplementary figure 1: Overview of the applied treatment modalities in the different 
treatment centers 
 
Each letter represents one center with the radiotherapy modality type indicated in color (red: 
SBRT, blue: ENRT).  
  
Statistical analysis 
Bootstrap analysis 
Following a bootstrap  evaluation of the LASSO procedure for variable selection, we found 
that the full set of selected variables was quite variable, but in 75% of the cases the LASSO 
added the interaction between RT and lymph nodes amongst the variables selected, as on the 
original data. When fitting the parsimonious model involving all main effects plus this 
interaction across 2000 bootstrap samples,  a positive interaction effect was estimated in 
more than 95% of the bootstrap samples.  Together this leads us to propose to examine the 
hypothesis of the existence of  such interaction in a future RCT. A more detailed description 
of the used method can be found below.  
 
The stability of the analyses was tested as follows: 
1. A bootstrap on the complete procedure (LASSO/Coxph/Pruning of interactions) 
2. A bootstrap with the thus selected variable set, i.e. `final model’, only (all main 
effects plus the interaction between RT and number of nodes) 
3. Forward selection of interactions, starting with a model including all main effects. 
Interactions between RT and a confounder were only examined if the main effects for the 
confounder was statistically significant 
In the first bootstrap-analysis, the interaction between RT and number of nodes, is retained in 
45% of the bootstraps (75% if only LASSO is considered and pruning is not performed). 
However, the model fitted with the retained set of variables (all main effects plus interaction 
between RT and number of nodes), does provide a stable image over the different bootstrap 
samples. In more than 95% of the bootstrap samples, the estimate for the coefficient of the 
interaction is positive (see supplementary figure 2). Thus, the qualitative image that the final 
model provides, does hold over the different bootstrap samples. 
Exploring forward selection of interactions with RT starting from a model including all main 
effects and only testing interactions with RT for statistically significant confounders, leads to 
the same final model. 
 
  
Supplementary figure 2: graphic representation of 2000 bootstraps where the cox-model with all 
main effects plus an interaction between RT and number of nodes is fitted in each bootstrap.  
 
The x-axis represents the HR of the main effect of type of radiotherapy. The y-axis represents the HR 
of the interaction of type of radiotherapy and number of nodes. Remark the logarithmic scale on both 
axes. The blue dashed lines indicate a HR of 1. The blue dot represents the final model with the HR 
for the main effect of 0.5 and the HR for the interaction of 1.84. As seen in the figure, 95% of the 
bootstraps are in the same quadrant of the final model, indicating comparable results in the same 
direction with a HR of the main effect lower than 1 in combination with a HR of the interaction higher 
than 1. HR: hazard ratio 
  
Supplementary table 1: Multivariable analysis of metastasis-free survival 
Variable  HR (95% CI) 
Type of RT SBRT versus ENRT 0.5 (0.3-0.85) 
Age at time of diagnosis Median age (63y) 1.01 (0.98-1.04) 
Age difference* Median difference 
(5y) 
0.99 (0.94-1.04) 
EAU risk group Local versus locally 
advanced 
1.26 (0.88-1.8) 
Primary treatment RP versus RT 1.82 (1.06-3.13) 
Primary treatment RP versus RP+RT 2.03 (1.31-3.15) 
Extent of nodal disease N1 versus M1a 1.22 (0.85-1.75) 
Adjuvant ADT No versus yes 0.85 (0.6-1.21) 
PSA at recurrence ≤4 versus >4 1.42 (0.99-2.04) 
Number of nodes 1 versus >1 1.17 (0.72-1.91) 
Interactions   
Type of RT and number of nodes° SBRT versus ENRT 
and 1 versus >1 
1.84 (0.87-3.86) 
due to missing values, only 496 observations were retained.  
The variables not accentuated in bold correspond to the baseline values. The variables 
accentuated in bold are the variables that correspond with the HR. °  The HR of the 
interactions are calculated by multiplying the HR of the individual variables. For patients 
presenting with more than 1 node, the HR for ENRT versus SBRT is 0.5x1.84=0.92 
 
*Age difference between diagnosis and recurrence; represents time from diagnosis to 
recurrence 
 
 
 
 
 
 
 
 
Supplementary table 2: Detailed overview of the observed toxicities 
 
  SBRT (n=309) ENRT (n=197) 
Toxicity GU GI GU & GI Other GU GI GU & GI Other 
Early, n (%) 
Grade 1 
Grade 2 
Grade 3 
Grade 4 
  
1 (0.3) 
1 (0.3) 
0 (0) 
0 (0) 
  
0 (0) 
0 (0) 
0 (0) 
0 (0) 
  
0 (0) 
0 (0) 
0 (0) 
0 (0) 
  
1 (0.3) 
0 (0) 
0 (0) 
0 (0) 
  
4 (2) 
2 (1) 
1 (0.5) 
0 (0) 
  
2 (1) 
3 (2) 
0 (0) 
0 (0) 
  
0 (0) 
0 (0) 
0 (0) 
0 (0) 
  
0 (0) 
0 (0) 
0 (0) 
0 (0) 
Late, n (%) 
Grade 1 
Grade 2 
Grade 3 
Grade 4 
  
6 (2) 
1 (0.3) 
0 (0) 
0 (0) 
  
5 (2) 
2 (0.6) 
0 (0) 
0 (0) 
  
0 (0) 
0 (0) 
0 (0) 
0 (0) 
  
3 (1) 
0 (0) 
0 (0) 
0 (0) 
  
6 (3) 
7 (4) 
3 (2) 
0 (0) 
  
2 (1) 
6 (3) 
0 (0) 
0 (0) 
  
1 (0.5) 
0 (0) 
0 (0) 
1 (0.5) 
  
2 (1) 
3 (2) 
0 (0) 
0 (0) 
Total 9 (3) 7 (2) 0 (0) 4 (1) 23 (12) 13 (7) 2 (1) 5 (3) 
ENRT: elective nodal radiotherapy; GI: gastro-intestinal; GU: genito-urinary; SBRT: 
stereotactic body radiotherapy 
 
  
Tables 
 
Table 1. Patient and tumor characteristics.  
Patient characteristic SBRT  
n= 309, 61% 
ENRT  
n=197, 39% 
Age at PCa diagnosis, years 
Median (IQR) 
 
63 (58 - 68) 
 
63 (59 - 68) 
PSA at PCa diagnosis, ng/mL 
Median (IQR) 
 
9.3 (6.7 – 14.0) 
 
9.2 (6.7 – 16) 
EAU risk group classification, n 
(%) 
Localized disease 
Locally advanced 
Unknown 
 
125 (40) 
178 (58) 
6 (2) 
 
69 (35) 
128 (65) 
0 (0) 
Type of primary treatment, n 
(%) 
RP only 
RT only 
RP and RT 
 
87 (28) 
66 (21) 
156 (50) 
 
67 (34) 
29 (15) 
101 (51) 
RT field, n (%) 
Prostate bed only 
Whole pelvis RT 
n=222 
204 (92) 
18 (8) 
n=130 
120 (92) 
10 (8) 
PLND at primary treatment, n 
(%) 
No  
 
168 (54) 
141 (46) 
 
100 (51) 
97 (49) 
Yes 
Median n of nodes 
removed,  (IQR) 
pN0 
pN1 
Median n of nodes 
positive if pN1, 
(IQR) 
 
 
8 (5-12) 
122 (87) 
19 (13) 
 
 
1 (1-3) 
 
 
8 (4-14) 
85 (88) 
12 (12) 
 
 
2 (2-4) 
 
ADT at primary treatment, n 
(%)  
No 
Yes 
Unknown 
 
159 (51) 
120 (39) 
30 (10) 
 
130 (66) 
63 (32) 
4 (2) 
Age at recurrence, years 
Median (IQR) 
 
69 (64 – 74) 
 
68 (64 – 72) 
PSA at recurrence, ng/mL 
Median (IQR) 
 
2.7 (1.3 – 5.6) 
 
2.5 (1.2 – 4.9) 
PSA-DT at recurrence, months* 
Median (IQR) 
 
6.0 (4.0 – 10.9) 
 
5.0 (3.0 – 8.6) 
Metastatic site, n (%) 
Pelvic 
Extrapelvic  
Pelvic + extrapelvic 
 
222 (72) 
69 (22) 
18 (6) 
 
143 (73) 
29 (15) 
25 (13) 
N of positive nodes at imaging,  
n (%) 
1 metastasis 
2 metastases 
3 metastases 
4 metastases 
5 metastases 
 
 
243 (79) 
50 (16) 
13 (4) 
2 (1) 
1 (<1) 
 
 
98 (50) 
55 (28) 
23 (12) 
13 (7) 
8 (4) 
Adjuvant ADT at time of 
recurrence, n (%) 
No 
Yes 
Unknown 
Median duration of ADT, 
months (IQR) 
 
 
237 (77) 
71 (23) 
1 (<1) 
6 (3 – 11) 
 
 
78 (40) 
119 (60) 
0 (0) 
6 (6 – 9)  
* in the SBRT group we note 100 (32%) missing values compared to 29 (15%) missing values  in the ENRT group. ADT: 
androgen-deprivation therapy; ENRT: elective nodal radiotherapy; IQR: interquartile range; PLND: pelvic lymph node 
dissection; pN0: pathologically confirmed N0 state after PLND; pN1: pathologically confirmed N1 state after PLND; PSA: 
prostate-specific antigen; PSA-DT: prostate-specific antigen doubling time; RP: radical prostatectomy; RT: radiotherapy; 
SBRT: stereotactic body radiotherapy 
 
  
Table 2: pattern of progression following SBRT or ENRT. 
Metastatic location SBRT  
n=309, 61% 
ENRT  
n=197, 39% 
p-value 
Node, n  
Pelvic 
Extrapelvic 
Pelvic + extrapelvic 
131  
55  
34  
42  
40  
3  
32  
5  
<0.001 
Bone, n  
Axial 
Non-axial 
Axial + non-axial 
35  
17  
13  
5  
26  
12  
7  
7  
0.6 
Prostate bed, n  1  2  0.6 
Visceral, n  10  6  >0.9 
Total, n  177  74  <0.001 
In case of a combination (M1a – b – c), the highest metastatic definition is applied. The main  sites of recurrence are 
highlighted in bold. ENRT: elective nodal radiotherapy; SBRT: stereotactic body radiotherapy 
 
 
 
 
